GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (NAS:THMO) » Definitions » Net Cash per Share

ThermoGenesis Holdings (ThermoGenesis Holdings) Net Cash per Share : $-3.01 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). ThermoGenesis Holdings's Net Cash per Share for the quarter that ended in Dec. 2023 was $-3.01.

The historical rank and industry rank for ThermoGenesis Holdings's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of ThermoGenesis Holdings was 90.05. The lowest was 90.05. And the median was 90.05.

THMO's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.16
* Ranked among companies with meaningful Price-to-Net-Cash only.

ThermoGenesis Holdings Net Cash per Share Historical Data

The historical data trend for ThermoGenesis Holdings's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Net Cash per Share Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -184.70 -39.78 -36.05 -10.52 -3.01

ThermoGenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.52 -5.09 -3.76 -2.33 -3.01

Competitive Comparison of ThermoGenesis Holdings's Net Cash per Share

For the Medical Devices subindustry, ThermoGenesis Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Price-to-Net-Cash falls into.



ThermoGenesis Holdings Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

ThermoGenesis Holdings's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2-14.816--1.917)/3.61789
=-3.01

ThermoGenesis Holdings's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2-14.816--1.917)/3.61789
=-3.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (NAS:THMO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


ThermoGenesis Holdings Net Cash per Share Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (ThermoGenesis Holdings) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
Executives
Xiaochun Xu director 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu director 2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu director 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph director MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford director 7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate director 350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble officer: Principal Accounting Officer 2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu director
Boyalife Investment Inc. 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545

ThermoGenesis Holdings (ThermoGenesis Holdings) Headlines

From GuruFocus